Nutrien (NTR) Q2 2026 Earnings Call Transcript

Nutrien reported Q2 adjusted EBITDA of $2.43B (down 2% YoY) but said first-half adjusted EBITDA rose 6% to $3.5B, supported by record potash volumes (3.9M tonnes). The company raised 2026 potash volume guidance to 14.2–14.8M tonnes and kept retail adjusted EBITDA guidance at $1.75B–$1.95B, while lowering capex guidance by $50M to $1.95B–$2.05B and increasing buybacks to ~$75M/month in Q3 (vs. ~$55M/month at start of year). Near-term sentiment is mixed: phosphate adjusted EBITDA fell to $23M (down 75% YoY) due to elevated sulfur costs, but management is constructive on potash demand and nitrogen despite geopolitical and El Niño risks.

Analysis

NTR is becoming less of a pure fertilizer beta and more of a capital-allocation/asset-simplification story. The market should reward the combination of low-cost potash optionality, a steadily shrinking capex burden, and buybacks that are now materially supported by divestiture proceeds; that is a better mix than peers whose equity value is still hostage to commodity swings. The second-order winner is the potash complex broadly, but NTR has a relative edge because automation and existing infrastructure let it add tonnage with far less incremental capital than greenfield competitors.

The main loser set is phosphate-heavy and sulfur-sensitive peers, where elevated input costs can force production cuts or margin destruction before end-demand visibly breaks. That matters because any forced discipline in phosphate tightens the broader nutrient basket and supports NTR’s pricing power in the near term, while also raising the probability that strategic buyers attach more value to NTR’s phosphate assets than the market is currently implying. In nitrogen, NTR’s North American feedstock advantage looks more durable than the market gives credit for if geopolitical disruptions keep European gas and global ammonia trade volatile.

The near-term risk is not the print itself but a reversal in farmer sentiment: if fall application is delayed by another leg down in grain prices, the deferred volumes can reappear as a margin disappointment rather than a volume tailwind. Over 1-3 months, the key catalyst is whether the repurchase pace stays elevated and whether the phosphate review turns nonbinding bids into a credible monetization path; over 6-18 months, Investor Day could re-rate the stock if management demonstrates that potash expansion is a high-ROIC brownfield story, not a capex creep story. Consensus is probably underestimating how much of the equity value can be de-risked by portfolio pruning alone, even without a strong fertilizer cycle.

Key Decisions for Investors

• Long NTR on post-earnings weakness for a 1-3 month hold; thesis is that buybacks, divestitures, and the phosphate review matter more than the modest EBITDA miss. Risk/reward: upside from multiple expansion if capital returns stay elevated; thesis breaks if repurchases revert below the current pace or if phosphate bids fail to progress by year-end.
• Pair trade: long NTR / short MOS over the next 2-4 months. NTR has better balance-sheet optionality, lower incremental potash capital intensity, and less earnings sensitivity to sulfur-driven phosphate stress. Fails if potash prices roll over faster than phosphate margins normalize.
• Watchlist alert on CF and other nitrogen proxies for a 1-3 month relative-value short if European gas remains elevated and nitrogen pricing inflects up again. NTR’s North American feedstock advantage should allow it to outperform higher-cost peers, but the trade only works if the geopolitical risk premium persists.
• Do not chase NTR higher on the call alone; wait for evidence that Q3 retail deferrals are converting into actual fall applications. If channel checks show weak fall fill or if potash demand slips back toward the low end of guidance, fade the move.